Waters Corporation (WAT) fair value analysis
S&P 500 · Updated 2026-10-19
WAT price how computed
Forward Fair Value verdict
Fairly valuedWAT is trading at within about 10% of estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $433.77
- Sector
- Healthcare
- 12-month range
- $283.32–$444.15
- Market cap
- $42.6B
- From 52-week high
- -2.3%
- Shares outstanding
- 98.2M
- Rank in Healthcare by discount to fair value
- #54 of 108
Last price is our 2026-10-19 weekly price; the chart runs through 2026-10-16.
Waters Corporation is a manufacturer and provider of laboratory instruments, software, and services used for chemical analysis and testing across various industries including pharmaceuticals, food and beverage, environmental monitoring, and academic research. The company operates globally with a presence in multiple countries across North America, Europe, Asia, and other regions.
WAT currently ranks #54 of 108 Healthcare stocks by discount to fair value. It has screened as Fairly valued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $42.6B
- P/E (trailing)
- 32x
- Revenue (TTM)
- $4.64B
- Net margin
- 3.6%
- EPS (TTM)
- $13.68
- Gross margin
- 44.6%
- Debt / equity
- 0.35
- Revenue growth (3-yr avg)
- 43.7%
- Shares outstanding
- 98.2M
Derived indicators how computed
- Quality grade
- B
- Margin trend
- Contracting
- 52-week position
- The top quarter of its range
Technicals how computed
- RSI (14-day)
- 53 · neutral
- 50-day average
- $420.52
- 200-day average
- $366.23
- Moving-average state
- 50-day above 200-day (golden cross state); price above both averages
Earnings how computed
- Next earnings report
- 2026-11-03 (pre-market)
- Last 8 quarters vs consensus
- 8 beat, 0 missed
- Quarter by quarter
- 2026-06 ▲ beat (+1.3%)
2026-03 ▲ beat (+16.9%)
2025-12 ▲ beat (+0.4%)
2025-09 ▲ beat (+5.6%)
2025-06 ▲ beat (+0.3%)
2025-03 ▲ beat (+1.4%)
2024-12 ▲ beat (+1.7%)
2024-09 ▲ beat (+9.3%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 18 buy · 6 hold · 0 sell (24 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $464
- Target vs last price
- +7.0%
What our data shows for WAT
- Our model validated 17 trailing price-to-earnings windows for WAT, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $283.32–$444.15.
- The 14-day relative strength index sits at a neutral 53.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for WAT
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent WAT news
TickrTrends' derived news-sentiment signal for WAT is currently leaning positive, computed from recent coverage.
- Waters: Positive Momentum Rides High Again (NYSE:WAT) (seekingalpha.com, 2026-09-23)
TickrTrends take: Waters Corporation trades at a Fairly valued assessment according to TickrTrends, suggesting the market price currently aligns with underlying fundamentals for a Healthcare sector company. The reported positive momentum warrants monitoring of whether such operational strength can translate into earnings growth that justifies maintaining this valuation level. Investors focused on valuation should track whether this momentum sustains or contracts, as either outcome could shift the fair value perception in coming periods. - WAT Looks 2.4% Overvalued on GF Value™ as Piper Sandler Boosts Price Target (gurufocus.com, 2026-08-27)
TickrTrends take: Waters Corporation operates in the Healthcare sector and currently holds a Fairly valued designation according to TickrTrends analysis. The recent analyst action from Piper Sandler represents a positive development that contrasts with the GF Value assessment suggesting modest overvaluation, creating a divergence that investors monitoring valuation metrics should track closely. For those focused on valuation fundamentals, this gap between analyst enthusiasm and intrinsic value estimates warrants observation as new data emerges.
What people are saying
Follow the WAT conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends' derived indicators show that WAT has moved to a higher sector discount rank this week, shifting from number 59 to number 64 among Healthcare sector stocks. The company maintains a Fairly valued valuation verdict as of the current assessment period.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is WAT stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), WAT is trading at within about 10% of estimated fair value and screens as fairly valued. The exact fair value and discount are available to subscribers.
What is WAT's TickrTrends verdict?
WAT's current verdict is Fairly valued, refreshed with every weekly Forward Fair Value run.
How does WAT compare to other Healthcare stocks?
WAT ranks #54 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is WAT overbought or oversold?
WAT's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does WAT report earnings next?
WAT's next earnings report is scheduled for 2026-11-03 (pre-market), per the published earnings calendar.
Does WAT usually beat earnings estimates?
Over its last 8 reported quarters WAT beat the consensus estimate 8 times and missed 0 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about WAT?
Of 24 analysts covering WAT, 18 rate it a buy, 6 a hold and 0 a sell - buy-leaning, with a consensus price target of $464 (+7.0% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
WAT vs ACHC · WAT vs COR · WAT vs DHR · WAT vs HCA · WAT vs HCSG